- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05041660
Using Virtual Reality and Sensor Technology to Enhance Outcomes From Treatment for Binge Eating
Study Overview
Status
Conditions
Detailed Description
Low levels of inhibitory control (i.e., the ability to withhold a quick, automatic response) is strongly linked with binge eating pathology. One of the most widely used and effective treatments for binge eating leaves 40-60% of patients partially or fully symptomatic at post-treatment. Researchers have begun to investigate the efficacy of computerized inhibitory control trainings (ICTs), which are tasks in which participants are asked repeatedly withhold a keypress responses to food stimuli. The intention of these trainings is to improve inhibitory control and to, in turn, reduce dysregulated eating behavior.
Results for the efficacy of ICTs are promising, yet mixed. ICTs that are gamified (i.e., turned into a video game) using virtual reality technology have high potential to address the barriers which may be limiting the efficacy of previous ICTs. The current study aims to finalize development and test the feasibility, acceptability and preliminary efficacy of the first-ever virtual reality ICT (VR-ICT) for individuals with binge eating pathology.
Thus, the study's aims are as follows:
Primary aim 1: Enhance features of a previously developed, VR-based ICT for binge eating.
Primary aim 2: Examine the feasibility and acceptability of the VR ICT training program.
Primary aim 3: Examine the efficacy of VR-ICT versus a non-VR ICT and ICT vs. sham training, for reductions in binge eating from pre to post-treatment and at follow-up.
Based on previous research and data from a pilot study, the investigators hypothesize a) that the VR ICT training program will be feasible and acceptable and b) that the VR-ICT and ICT will produce superior reductions in binge eating from pre- to post-treatment and at follow-up, as compared, respectively, with the non-VR ICT and the sham ICT.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Drexel Universitty
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Speak, write, and understand English
- Age 18-65 years
Experience objectively or subjectively large binge eating episodes once per week or more for the past three months
- Objectively large binge episodes are defined by the Eating Disorder Examination (EDE; a measure employed in this study) as consisting of at least two full meals of two courses at each (i.e., four courses total) or of at least three main courses
- Participants, also as per the EDE, must also experience a loss of control over their eating for the given episode to qualify as an objective binge
- Subjective binges are those which do not meet the food quantity criteria but during which participants experience a loss of control and feel they have eaten too much
- If applicable, have stable psychiatric medication for the past three months.
Exclusion Criteria:
- Acute suicide risk
- Are planning on receiving psychological treatment for binge eating during the course of their participation in the study
- Are planning to participate in a structured weight loss treatment program (e.g., WeightWatchers, behavioral weight loss treatment) during the course of their participation in the study
- Are currently receiving weight loss treatment
- Have a BMI below 17.5
- Co-morbid clinically significant psychological disorder that would require attention beyond the study treatment (i.e., bipolar I disorder, substance dependence, and/or psychotic conditions)
- Diagnosis of intellectual disability or autism spectrum disorder
- History of neurological condition or traumatic brain injury
- Current pregnancy or intention to become pregnant during the course of their participation
- History of bariatric surgery
- Are currently using a stimulant medication (e.g., Ritalin, Adderall)
- No internet connection at home
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: FACTORIAL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: VR ICT
Virtual-reality-based inhibitory control training done daily at home for 6 weeks.
|
Uses virtual reality for the inhibitory control training, rather than a relatively simplistic computerized training.
Other Names:
Uses an active inhibitory control training which includes a "stop" signal.
Other Names:
|
SHAM_COMPARATOR: VR Sham ICT
Virtual-reality-based sham inhibitory control training (i.e., one that does not include a "stop" signal and that thus does not truly train inhibitory control) done daily at home for 6 weeks.
|
Uses virtual reality for the inhibitory control training, rather than a relatively simplistic computerized training.
Other Names:
Uses an inhibitory control training which does not include a "stop" signal.
|
ACTIVE_COMPARATOR: Non-VR ICT
Computerized inhibitory control training done daily at home for 6 weeks.
|
Uses an active inhibitory control training which includes a "stop" signal.
Other Names:
Uses a relatively simplistic computerized training.
|
SHAM_COMPARATOR: Non-VR Sham ICT
Computerized sham inhibitory control training (i.e., one that does not include a "stop" signal and that thus does not truly train inhibitory control) done daily at home for 6 weeks.
|
Uses an inhibitory control training which does not include a "stop" signal.
Uses a relatively simplistic computerized training.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Protocol recruitment
Time Frame: The investigators will assess adherence at follow-up assessments (18 weeks after baseline assessment)
|
This outcome will be assessed according to whether the investigators can recruit at least 40 participants.
This forms the first half of the assessment of the protocol's feasibility.
|
The investigators will assess adherence at follow-up assessments (18 weeks after baseline assessment)
|
Protocol retention
Time Frame: The investigators will assess adherence at follow-up assessments (18 weeks after baseline assessment)
|
This outcome will be assessed according to whether > 75% of participants completed all assessments.
This forms the second half of the assessment of the protocol's feasibility.
|
The investigators will assess adherence at follow-up assessments (18 weeks after baseline assessment)
|
Protocol adherence
Time Frame: The investigators will assess adherence at follow-up assessments (18 weeks after baseline assessment).
|
This outcome will be assessed according to whether participants completed ≥ 75% of all daily training sessions.
This forms the first half of the assessment of the protocol's acceptability.
|
The investigators will assess adherence at follow-up assessments (18 weeks after baseline assessment).
|
Protocol satisfaction
Time Frame: The investigators will assess satisfaction at follow-up assessments (18 weeks after baseline assessment).
|
This outcome will be assessed according to whether the average participant rating is >= 4 on all questions on the Technology Reactions and Acceptance and Technology Expectancy Questionnaires.
This forms the second half of the assessment of the protocol's acceptability.
|
The investigators will assess satisfaction at follow-up assessments (18 weeks after baseline assessment).
|
Impact of VR + ICT vs. VR + Sham on binge eating frequency
Time Frame: The investigators will assess efficacy at post-treatment (6 weeks after baseline) and at follow-up (18 weeks after baseline).
|
This outcome will be assessed according to whether participation in the VR + ICT condition produces a larger change in binge eating episodes than does participation in the VR + Sham condition, as measured using the binge module of the Eating Disorder Examination version 17.
|
The investigators will assess efficacy at post-treatment (6 weeks after baseline) and at follow-up (18 weeks after baseline).
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1906007227
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Binge Eating
-
ShireCompleted
-
Lindner Center of HOPEUniversity of CincinnatiCompleted
-
University of North Carolina, Chapel HillThe Hilda & Preston Davis Foundation; Global Foundation for Eating DisordersCompletedEating Disorder | Binge-eating DisorderUnited States
-
Sao Jose do Rio Preto Medical SchoolFundação de Amparo à Pesquisa do Estado de São PauloCompletedBinge-Eating Disorder | Eating Disorders | Eating Behavior | Eating Disorder | Binge Eating Disorder Associated With ObesityBrazil
-
BioprojetRecruiting
-
Lindner Center of HOPEJazz PharmaceuticalsRecruiting
-
Idorsia Pharmaceuticals Ltd.Completed
-
University of ChicagoTakedaCompleted
-
Drexel UniversityCompleted
Clinical Trials on Virtual-reality-based training
-
Mental Health Services in the Capital Region, DenmarkRigshospitalet, Denmark; University of Copenhagen; TrygFonden, DenmarkRecruitingDepression | Psychotic Disorders | Schizophrenia | Cognitive Impairment | Bipolar Disorder | Schizotypal DisorderDenmark
-
Vanderbilt UniversityUniversity of California, San DiegoCompleted
-
Inha University HospitalUnknownMild Cognitive ImpairmentKorea, Republic of
-
University of Massachusetts, LowellSpaulding Rehabilitation Hospital; Hugo W. Moser Research Institute at Kennedy...Recruiting
-
Riphah International UniversityCompletedPostmenopausal OsteopeniaPakistan
-
University of Illinois at ChicagoSuspendedStrokeUnited States
-
Seoul National University HospitalMinistry of Trade, Industry & Energy(MOTIE, Korea)CompletedVirtual Reality; Rehabilitation; Parkinson's DiseaseKorea, Republic of
-
Umm Al-Qura UniversityCompletedUpper Extremity Dysfunction | Spastic Hemiplegia | Spasticity as Sequela of StrokeSaudi Arabia
-
University of California, Los AngelesSuspendedDepression | Mood Disorders | Anhedonia | Stress | Anxiety | Virtual RealityUnited States
-
Second Affiliated Hospital of Wenzhou Medical UniversityTerminatedImmersion Virtual Reality Training ,Stroke, Upper Extremity, Randomized Controlled TrialChina